Published in Br J Pharmacol on December 01, 2002
Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol (2009) 1.51
The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol (2008) 1.26
ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol (2009) 1.13
Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol (2005) 1.05
Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II). Br J Clin Pharmacol (2004) 1.02
Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int (2013) 0.98
Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol (2010) 0.95
Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease. Clin Pharmacol Ther (2010) 0.90
Effects of uremic toxins on transport and metabolism of different biopharmaceutics drug disposition classification system xenobiotics. J Pharm Sci (2011) 0.87
Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol (2008) 0.83
Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol (2010) 0.80
Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. J Lipid Res (2013) 0.79
In vivo alterations in drug metabolism and transport pathways in patients with chronic kidney diseases. Pharmacotherapy (2013) 0.78
Effects of chronic kidney disease on liver transport: quantitative intravital microscopy of fluorescein transport in the rat liver. Am J Physiol Regul Integr Comp Physiol (2014) 0.78
Gender-Dimorphic Impact of PXR Genotype and Haplotype on Hepatotoxicity During Antituberculosis Treatment. Medicine (Baltimore) (2015) 0.77
CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease. Br J Clin Pharmacol (2015) 0.76
Effect of erythropoietin on hepatic cytochrome P450 expression and function in an adenine-fed rat model of chronic kidney disease. Br J Pharmacol (2014) 0.75
Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum. Clin Pharmacol (2013) 0.75
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12. Clin Pharmacol Drug Dev (2016) 0.75
Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients. Springerplus (2016) 0.75
Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521). Pulm Circ (2016) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. J Biol Chem (1964) 24.57
Preparation of isolated rat liver cells. Methods Cell Biol (1976) 17.96
Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int (1999) 4.25
Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol (1993) 1.72
Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol (2001) 1.39
Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos (2000) 1.24
cAMP-associated inhibition of phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocyte cultures. J Biol Chem (1995) 1.13
Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf (1997) 1.11
Drug dosing in renal insufficiency. J Clin Pharmacol (1994) 1.07
The effect of renal failure on hepatic drug clearance. DICP (1991) 1.06
Oxidative drug metabolism in liver microsomes from uremic rats. Kidney Int (1972) 1.06
Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest (1996) 1.06
Drug prescribing for patients with changing renal function. Am J Hosp Pharm (1992) 1.05
In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant (1995) 1.00
Abnormalities in hepatic lipase in chronic renal failure: role of excess parathyroid hormone. J Clin Invest (1996) 0.97
Changes of hepatic microsomal oxidative drug metabolizing enzymes in chronic renal failure (CRF) rats by partial nephrectomy. Jpn J Pharmacol (1995) 0.94
Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol (1984) 0.93
Enzyme induction in the uremic liver. Kidney Int Suppl (1978) 0.92
Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol (1996) 0.91
Renal disease and drug metabolism: an overview. Am J Kidney Dis (1986) 0.91
Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood. J Pharmacol Exp Ther (1985) 0.90
Hepatic oxidative drug metabolism in rats with experimental renal failure. Arch Int Pharmacodyn Ther (1977) 0.88
Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1-stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol (1999) 0.86
Role of the systemic inflammatory response syndrome in the development of protein-calorie malnutrition in ESRD. Am J Kidney Dis (1998) 0.86
Interleukin-1 beta antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture. FEBS Lett (1995) 0.85
Transforming growth factor-beta 1 down-regulates basal and polycyclic aromatic hydrocarbon-induced cytochromes P-450 1A1 and 1A2 in adult human hepatocytes in primary culture. Mol Pharmacol (1994) 0.84
Increased production of interleukin-1beta and interleukin-1 receptor antagonist by peripheral blood mononuclear cells in undialyzed chronic renal failure. Nephron (1997) 0.83
Chronic renal failure is a state of cellular calcium toxicity. Am J Kidney Dis (1993) 0.83
A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1994) 0.82
Mechanisms of PTH-induced rise in cytosolic calcium in adult rat hepatocytes. Am J Physiol (1994) 0.81
Chronic renal failure increases cytosolic Ca2+ of hepatocytes. Am J Physiol (1995) 0.81
Pharmacokinetics of cefmenoxime in patients with impaired renal function and in those undergoing hemodialysis. Antimicrob Agents Chemother (1986) 0.80
The effect of uremia on tumor necrosis factor-alpha release after an in vitro whole-blood endotoxin challenge. J Am Soc Nephrol (1994) 0.78
Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int (1994) 0.78
Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol (2009) 2.12
Rationale for heating oxaliplatin for the intraperitoneal treatment of peritoneal carcinomatosis: a study of the effect of heat on intraperitoneal oxaliplatin using a murine model. Ann Surg (2011) 2.09
Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis (2005) 1.92
Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis (2005) 1.69
ESRD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol (2009) 1.13
Palmitoylation controls recycling in lysosomal sorting and trafficking. Traffic (2008) 1.12
Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos (2007) 1.10
Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol (2005) 1.05
Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther (2006) 1.03
Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res (2006) 1.00
Transplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment. Stem Cells (2013) 1.00
Successful treatment of encapsulating peritoneal sclerosis with immunosuppressive therapy. Am J Kidney Dis (2008) 1.00
Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol (2002) 1.00
Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol (2006) 0.98
Reduced hepatic synthesis of calcidiol in uremia. J Am Soc Nephrol (2010) 0.95
Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos (2011) 0.94
Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci (2008) 0.92
Atheroembolic renal failure requiring dialysis: potential for renal recovery? A review of 43 cases. Nephron Clin Pract (2003) 0.91
Current understanding of drug disposition in kidney disease. J Clin Pharmacol (2012) 0.90
Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends. BMC Nephrol (2013) 0.88
Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol (2004) 0.87
Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: a prospective study. Diabetes Res Clin Pract (2013) 0.86
Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators. Br J Pharmacol (2002) 0.85
Interleukin-1beta, interleukin-6, tumour necrosis factor-alpha and interferon-gamma released by a viral infection and an aseptic inflammation reduce CYP1A1, 1A2 and 3A6 expression in rabbit hepatocytes. Eur J Pharmacol (2003) 0.84
Magnitude of discordance between registry data and death certificate when evaluating leading causes of death in dialysis patients. BMC Med Res Methodol (2013) 0.84
Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol (2008) 0.83
Acute Kidney Injury and Renal Recovery with the Use of Aminoglycosides: A Large Retrospective Study. Nephron (2015) 0.81
Microencapsulation of living cells in semi-permeable membranes with covalently cross-linked layers. Biomaterials (2005) 0.80
Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians. Drug Metab Pharmacokinet (2010) 0.80
Characterization of two novel cold-inducible K3 dehydrin genes from alfalfa (Medicago sativa spp. sativa L.). Theor Appl Genet (2012) 0.80
Urinary monocyte chemotactic protein 1: marker of renal function decline in diabetic and nondiabetic proteinuric renal disease. J Nephrol (2010) 0.79
A case of an aortic dissection in a young adult: a refresher of the literature of this "great masquerader". Int J Gen Med (2011) 0.78
Bicarbonates for the prevention of postoperative renal failure in endovascular aortic aneurysm repair: a randomized pilot trial. Anesthesiol Res Pract (2013) 0.78
Effects of chronic renal failure on brain drug transporters in rats. Drug Metab Dispos (2011) 0.77
Complement dysregulation in haemolytic uraemic syndrome. Lancet (2003) 0.77
Restoration of renal function by a novel prostaglandin EP4 receptor-derived peptide in models of acute renal failure. Am J Physiol Regul Integr Comp Physiol (2012) 0.76
Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients. BMC Nephrol (2014) 0.76
Down-regulation of liver drug-metabolizing enzymes in a murine model of chronic renal failure. Drug Metab Dispos (2009) 0.76
Comparison of the prevalence of calcidiol insufficiency in predialysis and osteoporotic populations. Int Urol Nephrol (2008) 0.76
Calcidiol deficiency in CKD patients: the role of reduced liver synthesis. Am J Kidney Dis (2012) 0.75
Evidence that the mouse osteocalcin-related gene does not encode nephrocalcin. Nephron Exp Nephrol (2006) 0.75
Effect of parathyroidectomy on vitamin D levels. World J Surg (2015) 0.75
Treatment of gram-positive peritonitis in peritoneal dialysis patients: cefazolin or vancomycin? Perit Dial Int (2004) 0.75
Influence of SLCO1B3 genetic variations on tacrolimus pharmacokinetics in renal transplant recipients. Drug Metab Pharmacokinet (2012) 0.75
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D. Int Urol Nephrol (2015) 0.75
The role of sevelamer carbonate in increasing serum bicarbonate in hyperphosphatemic predialysis patients who have metabolic acidosis. Int J Clin Pharmacol Ther (2013) 0.75
Use of a fluorescent substrate for the selective quantification of rat CYP3A in the liver and the intestine. J Pharmacol Toxicol Methods (2006) 0.75
An interprofessional team that includes a nurse practitioner and patients with diabetes and chronic kidney disease. CANNT J (1) 0.75
Efficacy of calcitriol compared to alfacalcidol for the treatment of secondary hyperparathyroidism in peritoneal dialysis patients. Int J Clin Pharmacol Ther (2015) 0.75
Hemodialysis effects on phenytoin pharmacokinetics. Eur J Clin Pharmacol (2014) 0.75